Exelixis
@ExelixisInc
Followers
6K
Following
64
Media
1K
Statuses
1K
Biotechnology company striving to accelerate the development of new medicines for difficult-to-treat cancers. See our guidelines: https://t.co/bjFwsNq1eQ
Alameda, CA
Joined October 2010
Just announced: Detailed results from the phase 3 pivotal trial of $EXEL novel oral kinase inhibitor in combination with an immune checkpoint inhibitor in metastatic #ColorectalCancer presented at #ESMO25 and published in @TheLancet. Learn more: https://t.co/FpNvcjb5zR.
0
1
1
See results from a subgroup analysis of the phase 3 pivotal trial evaluating $EXEL flagship therapy in patients with advanced #NeuroendocrineTumors (NET) at #ESMO25. Learn more: https://t.co/dWigYfE8em.
0
1
2
ATTN Investors: $EXEL Q2 earnings announcement details available here: https://t.co/j2kij3svWN.
0
1
1
NEWS: Our partner Ipsen received European Commission approval of $EXEL flagship therapy for patients with previously treated advanced #NeuroendocrineTumors (NET). Learn more: https://t.co/ttf6lGmfC4.
0
2
6
Positive findings announced from a phase 3 pivotal trial of $EXEL third-generation TKI in combination with an immunotherapy in patients with metastatic #ColorectalCancer. Details available here: https://t.co/h73ecWos9W.
0
1
4
Just announced: Our partner Ipsen received a positive CHMP opinion in the EU for $EXEL flagship therapy for patients with previously treated advanced #NeuroendocrineTumors. Learn more: https://t.co/2eQxf7s99s.
0
1
7
See results from an expansion cohort of the phase 1b/2 study of our third-generation TKI in combination with immune checkpoint inhibitors in advanced #KidneyCancer at #ASCO25. Data from multiple dose-finding cohorts will also be presented: https://t.co/5mlk3Yjj3m. $EXEL
0
2
2
Dusty finds strength through family connection, self-advocacy and learning as much as she can following her diagnosis of #NeuroendocrineTumors (NET). Watch as Dusty shares her experiences and the many sources of hope in her life.
0
2
1
ATTN Investors: $EXEL Q1’25 earnings announcement details available here: https://t.co/LT920FpVoj.
0
1
2
We appreciated the opportunity to support this year's @AACRFoundation Scientist <-> Survivor program, which fosters relationships between scientific and advocacy community leaders. #AACR25
The @AACR Scientist↔Survivor Program® creates enduring partnerships among cancer survivors, advocates, and scientists. By strengthening collaboration, #AACRSSP helps improve clinical trial design and enhance access to cancer information. Learn more: https://t.co/pmgl0cR3OS
0
2
3
See our 2024 Annual Report to learn how the growth of our flagship therapy is further fueling a new generation of our medicines: https://t.co/hfDNodp3Dg. $EXEL
1
0
1
NEWS: We are excited to announce that the U.S. Food and Drug Administration has approved $EXEL flagship therapy for the treatment of previously treated advanced #NeuroendocrineTumors (NET). Details here: https://t.co/JPhgRg99vm.
3
5
12
Preclinical data from four $EXEL pipeline molecules to be presented for the first time at #AACR25. Read more: https://t.co/U0730VTzkO.
0
1
2
Final 5-year results from trial of $EXEL flagship product in combination with @BMSnews immunotherapy for patients with advanced #KidneyCancer presented at #GU25. Read more: https://t.co/WIKY4BeWQy.
0
1
3